@drtoomertalks's dosing advice for compounded GLP-1s checked

What did @drtoomertalks actually say?

The core message here is straightforward: if you are taking compounded semaglutide or tirzepatide, you should know your dose in milligrams, not in units, milliliters, or syringe lines. The doctor states plainly that "if you don't know what you're taking in milligrams, you have no idea if you're on an effective dose." She also lists the FDA-approved titration schedules for Ozempic, Wegovy, and Mounjaro/Zepbound as reference points. The secondary argument is that compounded pharmacy dosing does not always match manufacturer dosing when you do the math, and that patients switching between compounded and brand products could be flying blind without milligram-based knowledge.

She is not prescribing doses or claiming compounded drugs are equivalent to branded ones. She is making a patient safety argument about unit literacy. That is an important distinction.

Does the science back this up?

Yes, substantially. Dosing confusion in GLP-1 therapy is a documented patient safety concern, not a hypothetical one. The FDA issued a safety communication in 2023 specifically warning about medication errors with compounded semaglutide, citing cases where patients received doses in units more commonly associated with insulin, leading to dosing errors of up to tenfold. The agency repeated these warnings in 2024 as compounded GLP-1 use expanded.

A 2024 analysis in JAMA Internal Medicine (Downing et al.) found significant variability in compounded semaglutide products available online, with some products failing to meet labeled concentrations. If a product's concentration differs from what's assumed, then dosing by volume alone produces unpredictable actual milligram delivery. The math point the doctor raises, that titration doses "don't even equal any dose of the manufacturer," is consistent with this evidence. Knowing the milligrams per milliliter concentration of your specific compounded vial is, in fact, the only way to verify you are taking a meaningful dose.

What did they get wrong (or right)?

Mostly right, with a few rough edges. The titration schedules she cites are accurate for the branded products. Ozempic starts at 0.25 mg, Wegovy at 0.25 mg up to 2.4 mg, and tirzepatide (Mounjaro/Zepbound) from 2.5 mg to 15 mg. Those numbers match FDA-approved labeling.

One issue worth flagging: she conflates the concept of knowing your milligram dose with knowing whether you are on an "effective dose." These are related but not the same thing. Effective dosing in GLP-1 therapy is highly individual. Tolerability, weight loss response, and side effect burden all influence where a patient lands. A physician should be determining effective dosing, not a patient cross-referencing a printout. The milligram-literacy argument is valid for safety and continuity purposes. Framing it as the sole determinant of efficacy oversimplifies the clinical picture.

Her note that "not all compound pharmacies are made equally" is accurate and, if anything, understated. FDA inspections have found sterility and potency failures at some compounding facilities.

What should you actually know?

If you are using compounded semaglutide or tirzepatide, three things matter for your safety. First, confirm the concentration of your vial in milligrams per milliliter with your prescriber or pharmacist before drawing any dose. Second, never convert GLP-1 doses using insulin unit logic. The two drug classes use entirely different measurement systems. Third, if you transition from a compounded product to a branded one, or between compounded pharmacies, your prescriber needs to reassess your dose from scratch. Do not assume volume-to-volume equivalence.

It is also worth knowing that compounded GLP-1 products are not FDA-approved and are not required to demonstrate the same bioequivalence standards as branded drugs. The FDA placed semaglutide on its drug shortage list, which created a legal window for compounding. That window has been contested and is subject to ongoing regulatory change. Patients using these products should stay in contact with a licensed prescriber, not manage titration based on social media printouts alone, however well-intentioned.